Josh Brown is selling out of three of his top holdings in favor of momentum names for the "Halftime Report" Portfolio.» Read More
As investors await word on U.S. interest rate increases, quantitative easing certainly seems to be helping stock markets in Europe and Japan.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Monday: Stifel, Express Scripts, SunPower & more.
U.S. stocks pulled back from Friday's records to close narrowly mixed ahead of Fed Chair Janet Yellen's remarks over the next two days.
U.S. stock index futures signaled a lower open on Monday as uncertainty surrounded Greece's deal with its euro zone creditors.
With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.
U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.
Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.
NEW YORK, Feb 17- Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a 5 percent stake in agricultural equipment maker Deere& Co and said it shed a $3.74 billion investment in oil company Exxon Mobil Corp as oil prices plunged. The changes were among several that Berkshire made in its common stock investments in the fourth quarter, according to a U.S....
Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...
U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.
Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...
From a U.S. trading perspective, here are the ways to play the strengthening dollar of 2015.
Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...
Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.
SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....
Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...
One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.